Revance Therapeutics Inc
RVNC
Get informed when a big investor buys or sells
+ FollowMarket Cap$381.02M
Close$
$6.05
65.7% upside
Current Fair Value
65.7% upsideUndervalued by 65.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $381.02 Million |
|---|---|
| Enterprise Value | $847.26 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.83 |
| Beta | 0.95 |
| Outstanding Shares | 104,212,891 |
Return
| Return on Equity | 111.29% |
|---|---|
| Return on Assets | -39.31% |
| Return on Invested Capital | -42.89% |
Valuation & Multiples
| P/E Ratio | -0.95 |
|---|---|
| PEG | 1.27 |
| Price to Sales | 1.83 |
| Price to Book Ratio | -1.83 |
| Enterprise Value to Revenue | 3.43 |
| Enterprise Value to EBIT | -5.18 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.62 |
| Debt to Equity | -3.22 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 5, 2025
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Revance Therapeutics Inc
CEO: Mark Foley